Dovonex Psoriasis Ointment has been reclassified from POM to P, the MHRA announced today (August 17).

Containing the vitamin D analogue calcipotriol 50mcg/g, it is indicated for treating mild to moderate plaque psoriasis that has been previously diagnosed by a doctor in adults aged 18 years and over. The treatment is for application once daily, with a maximum duration of use of 12 weeks and a maximum pack size of 60g.

Dr Sarah Branch, MHRA’s deputy director of vigilance and risk management of medicines, said: “Psoriasis is a chronic disease, which can have a major impact on people’s quality of life. By making this medicine more widely available, patients will be able to treat flare ups quickly without the need for a prescription.”

The RPS welcomed the news. President Ash Soni commented: “Widening access to medicine is great news for patients. Pharmacists are already able to sell products for the treatment of psoriasis with appropriate advice on management, application and side effects. We welcome the addition of Dovonex Psoriasis Ointment to the range of products available.”

Widening access to medicine is great news for patients

Originally Published by Pharmacy Magazine

Recommended

Latest prescription stats published by NHS Digital

Nearly 1.02 billion items were dispensed by community pharmacies in 2016-17, according to figures issued by NHS Digital

Mental health in the spotlight

Mental health is in the news with new research findings, initiatives and a range of resources available to health profes...

Popular

September 2017 GPhC Registration Assessment Feedback

Our Graduate Officer, Beenish has written a report detailing feedback on the September 2017 registration assessment.

Oriel Applicant Feedback 2017

The BPSA have published a report detailing feedback on the Oriel application system for 2017.

Hospital Pharmacy Europe LIVE

The BPSA is pleased to announce its collaboration with Hospital Pharmacy Europe LIVE – a free-to-attend conference tak...